Ipilimumab Combination Dosing: Less is More

Clin Cancer Res. 2021 Aug 2:clincanres.2406.2021. doi: 10.1158/1078-0432.CCR-21-2406. Online ahead of print.ABSTRACTIpilimumab with and without anti-PD1 improved overall survival in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T cell trafficking and re-invigoration as likely mechanisms.PMID:34341015 | DOI:10.1158/1078-0432.CCR-21-2406
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research